Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as Buy by HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $120.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 109.68% from the stock’s previous close. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2031 earnings at $9.61 EPS.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. lifted their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Citigroup began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They set a “buy” rating and a $108.00 target price for the company. Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Chardan Capital reissued a “buy” rating and set a $115.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Stock Performance

ARWR traded up $1.33 during trading hours on Thursday, reaching $57.23. The company’s stock had a trading volume of 1,646,955 shares, compared to its average volume of 2,286,674. Arrowhead Pharmaceuticals has a 52 week low of $36.73 and a 52 week high of $95.49. The company’s 50-day moving average is $75.53 and its 200-day moving average is $75.98. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The firm has a market cap of $8.06 billion, a PE ratio of -25.44 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The firm had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. During the same period in the prior year, the business posted ($1.26) EPS. The firm’s quarterly revenue was up 171.0% compared to the same quarter last year. On average, equities analysts forecast that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insiders Place Their Bets

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc increased its position in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Optiver Holding B.V. increased its position in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $39,000. Finally, Allied Private Wealth LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $43,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.